184 related articles for article (PubMed ID: 28805961)
1. Reducing Branded Prescription Drug Prices: A Review of Policy Options.
Alexander GC; Ballreich J; Socal MP; Karmarkar T; Trujillo A; Greene J; Sharfstein J; Anderson G
Pharmacotherapy; 2017 Nov; 37(11):1469-1478. PubMed ID: 28805961
[TBL] [Abstract][Full Text] [Related]
2. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
3. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.
Padula WV; Ballreich J; Anderson GF
Appl Health Econ Health Policy; 2018 Dec; 16(6):753-763. PubMed ID: 30058011
[TBL] [Abstract][Full Text] [Related]
4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
5. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
Yeung K; Dusetzina SB; Basu A
JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
[TBL] [Abstract][Full Text] [Related]
6. Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
Hodgkin D; Horgan CM; Creedon TB; Merrick EL; Stewart MT
J Ment Health Policy Econ; 2015 Dec; 18(4):165-73. PubMed ID: 26729008
[TBL] [Abstract][Full Text] [Related]
7. Specialty pharmaceuticals: policy initiatives to improve assessment, pricing, prescription, and use.
Robinson JC; Howell S
Health Aff (Millwood); 2014 Oct; 33(10):1745-50. PubMed ID: 25288418
[TBL] [Abstract][Full Text] [Related]
8. Comparing employer-sponsored and federal exchange plans: wide variations in cost sharing for prescription drugs.
Buttorff C; Andersen MS; Riggs KR; Alexander GC
Health Aff (Millwood); 2015 Mar; 34(3):467-76. PubMed ID: 25732498
[TBL] [Abstract][Full Text] [Related]
9. Do interventions that address patient cost-sharing improve adherence to prescription drugs? A systematic review of recently published studies.
Sensharma A; Yabroff KR
Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):263-277. PubMed ID: 30628493
[TBL] [Abstract][Full Text] [Related]
10. Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions.
Doshi JA; Li P; Ladage VP; Pettit AR; Taylor EA
Am J Manag Care; 2016 Mar; 22(3):188-97. PubMed ID: 27023024
[TBL] [Abstract][Full Text] [Related]
11. Determinants of Market Exclusivity for Prescription Drugs in the United States.
Kesselheim AS; Sinha MS; Avorn J
JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
[TBL] [Abstract][Full Text] [Related]
12. Value-Based Pricing and Patient Access for Specialty Drugs.
Robinson JC; Howell S; Pearson SD
JAMA; 2018 Jun; 319(21):2169-2170. PubMed ID: 29801023
[No Abstract] [Full Text] [Related]
13. Specialty drug coupons lower out-of-pocket costs and may improve adherence at the risk of increasing premiums.
Starner CI; Alexander GC; Bowen K; Qiu Y; Wickersham PJ; Gleason PP
Health Aff (Millwood); 2014 Oct; 33(10):1761-9. PubMed ID: 25288420
[TBL] [Abstract][Full Text] [Related]
14. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
Rand LZ; Kesselheim AS
Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
[TBL] [Abstract][Full Text] [Related]
15. Barriers to Ensuring Access to Affordable Prescription Drugs.
Mello MM
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():275-289. PubMed ID: 31136248
[TBL] [Abstract][Full Text] [Related]
16. Fair global drug pricing.
Campbell JD; Kaló Z
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):581-583. PubMed ID: 30215535
[No Abstract] [Full Text] [Related]
17. The hidden cost of low prices: limited access to new drugs in India.
Berndt ER; Cockburn IM
Health Aff (Millwood); 2014 Sep; 33(9):1567-75. PubMed ID: 25201661
[TBL] [Abstract][Full Text] [Related]
18. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.
Gronde TV; Uyl-de Groot CA; Pieters T
PLoS One; 2017; 12(8):e0182613. PubMed ID: 28813502
[TBL] [Abstract][Full Text] [Related]
19. Share Of Specialty Drugs In Commercial Plans Nearly Quadrupled, 2003-14.
Dusetzina SB
Health Aff (Millwood); 2016 Jul; 35(7):1241-6. PubMed ID: 27385240
[TBL] [Abstract][Full Text] [Related]
20. Paying for On-Patent Pharmaceuticals: Limit Prices and the Emerging Role of a Pay for Outcomes Approach.
Fuller RL; Goldfield N
J Ambul Care Manage; 2016; 39(2):143-9. PubMed ID: 26945298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
